Disease-induced changes in the plasma binding of basic drugs.
about
pH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid)Decrease in penbutolol central response as a cause of changes in its serum protein bindingOptical studies on the specific interaction of dipyridamole with alpha 1-acid glycoprotein (orosomucoid).Human alpha-1-glycoprotein and its interactions with drugs.Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malariaDifferences in the serum binding determinants of isradipine and darodipine--consequences for serum protein binding in various diseasesTianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failureThe effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein.Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers.Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phasesDeterminants of plasma alpha 1-acid glycoprotein (AAG) concentrations in healthRelationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole bloodThe plasma protein binding of basic drugsRelationship between the transplacental gradients of bupivacaine and alpha 1-acid glycoprotein.Tocainide protein binding in normal volunteers and trauma patients.Serum alpha 1-acid glycoprotein and the binding of drugs in obesityA chemogenomic analysis of ionization constants--implications for drug discoveryRelationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.Study of the bioavailability of pindolol in malabsorption syndromesThe effects of age and smoking on the plasma protein binding of lignocaine and diazepam.Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor ImatinibPrinciples of pharmacotherapy: I. Pharmacodynamics.Revolutionary impact of nanodrug delivery on neuroscience.The cytokine response element of the rat alpha 1-acid glycoprotein gene is a complex of several interacting regulatory sequencesOrosomucoid, an acute response protein with multiple modulating activities.Disease states and drug pharmacokinetics.Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol.Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.Plasma and tissue binding considerations in drug disposition.Antiarrhythmic therapy: clinical pharmacology update.Derivatives of biarylalkyl carboxylic acid induce pleiotropic phenotypes in adult Schistosoma mansoni in vitro.Pharmacokinetics of quinine in chronic liver diseaseDecreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding.Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein.The plasma protein binding of metoclopramide in health and renal disease.Drug binding in sera deficient in lipoproteins, albumin or orosomucoid.Induction of propranolol metabolism by rifampicin.Stereoselective protein binding of alprenolol in the renal diseased state.Assessment of the contribution of alpha 1-acid glycoprotein to the serum binding of basic drugs using serum treated with sulphosalicylic acid and DEAE-cellulose.
P2860
Q24527329-1898603D-BD8A-4583-89B8-1BB12382F560Q28334243-7E41AA15-8A5F-476C-A2D5-6B458A74D789Q30411913-7618A651-D4A5-4DA0-BCD3-96686F4C698FQ34331335-A29DE040-D740-4FF8-ACAD-8A76DFE0C147Q34358656-64AC9F33-67E4-4A71-8289-4F834A4C82BFQ34398001-7297B2FD-E0A7-4FFD-A68C-95958C2C6BE0Q34398093-FE1C14A3-3830-4296-8184-1B2457FAFBE5Q34398214-BC8A3A3A-D375-41C6-B903-980F9E00AB2EQ34398308-38F35199-994C-4D56-895C-4FD5AA04E4E7Q34420976-2F9EE2F3-3E3C-4ADD-AAD3-FF8985C02005Q34446742-E2E74910-CA4F-4C2D-A688-56E354A078C2Q34447961-D949B8AD-841F-43F2-B1E9-AD2AEC97C283Q34448141-C04EB5FB-DA7C-4436-A195-03B641E5EAF0Q34449615-FFBCABFA-A34B-4981-AA3C-98CD2E4AFB00Q34449911-2F0E3C5B-8008-41B8-AE43-75A3A8D3CC52Q34514103-F385C8B2-8A49-43DF-A44A-5F09777FCB85Q34543267-E162D509-46AA-43F0-B126-E97497F6FE0BQ34621637-97EAE305-7ABC-4CCD-9DBD-F4BCFD91D6B7Q34621901-FA979653-5840-4DA8-A67A-42CB7318624CQ34622244-EFD73DC2-9480-46FC-91FC-BAEE995184D2Q34705820-A7174B42-19EB-4287-A3A1-EC5E8865E50FQ36313287-869E3C54-1C34-4987-9647-78E68DA6CF9BQ36460631-C9B73B16-08DE-4AE9-BDE7-BD3A927CD259Q36719063-A26E67FC-2A2A-41B2-A820-3F1AE997C2A7Q38364856-99F4205F-A04A-4AFA-9CFB-7D8AFBF0280CQ38689435-FBA47CA5-ABAE-4F25-A847-5AE2456AB19DQ38809021-EF5B7DF6-B47C-4F52-B17E-9E0CA0FF8B16Q39396657-9911442B-5FFB-42D5-BE0B-57F888D12059Q39851158-963E8A97-918C-4CDB-A3FD-1DE749525E21Q40153516-7324BA90-A887-4008-93EE-6B0288963EBFQ40187593-FA109204-2C5A-44FD-A961-412C8D59C3C6Q40657668-59866BA8-D7E1-499B-B3E4-0177CB1966FFQ42284748-3D01AD07-F777-4552-BD6F-F8DC469A6A20Q42531530-925FD611-669C-41D3-9101-47B18A144A55Q42531581-93C6215D-7408-41E6-B798-9F43C589DF42Q43240318-F92EDBC7-66B0-49B9-8E63-42BC59A14487Q43261943-E9B43293-CD44-485B-80EE-4284192F7D41Q43262011-805A6292-557F-464E-937E-094E79425E5CQ44060349-F01C9780-A75F-4754-9A1C-F931DB59D716Q44275538-73D1F331-937E-475B-A456-D81B55C52BE4
P2860
Disease-induced changes in the plasma binding of basic drugs.
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
1980年论文
@zh
1980年论文
@zh-cn
name
Disease-induced changes in the plasma binding of basic drugs.
@en
type
label
Disease-induced changes in the plasma binding of basic drugs.
@en
prefLabel
Disease-induced changes in the plasma binding of basic drugs.
@en
P1476
Disease-induced changes in the plasma binding of basic drugs.
@en
P2093
K M Piafsky
P304
P356
10.2165/00003088-198005030-00004
P577
1980-05-01T00:00:00Z
P6179
1017982872